Viridian Therapeutics
Open
$16.35
Prev. Close
$16.35
High
$16.38
Low
$16.31
Market Snapshot
$1.67B
-4.6
-3.05
$302K
252
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. The company is headquartered in Waltham, Massachusetts and currently employs 252 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. The company is headquartered in Waltham, Massachusetts and currently employs 252 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Recently from Cashu
Viridian Therapeutics Repays $55.1 Million Loan, Enhancing Financial Stability and Flexibility
Viridian Therapeutics (Ticker: VRDN) significantly enhances its financial position by repaying a $55.1 million term loan to Hercules Capital. This strategic move, completed in late May 2026, eliminate…
Viridian Therapeutics Repays $55.1 Million Loan, Enters Manufacturing Agreement with WuXi Biologics
Viridian Therapeutics (Ticker: VRDN) has successfully completed a significant financial maneuver by repaying approximately US$55.10 million of its Hercules term loan. This successful repayment marks a…
Viridian Therapeutics Announces Positive REVEAL-2 Trial Results and Raises $350 Million for Elegrobart Development
Viridian Therapeutics (Ticker: VRDN) has recently achieved a significant milestone with its announcement of positive topline results from the REVEAL-2 phase 3 clinical trial. This trial evaluates eleg…
Viridian Therapeutics Advances Proptosis Treatment with Promising Elegrobart Trial Results
Promising Advancements in Proptosis Treatment with Elegrobart Viridian Therapeutics is making significant strides in the treatment of proptosis, demonstrated by its recent REVEAL-1 trial involving the…